Trayt debuts mobile app to track and help treat autism, ADHD

Migraine headache/epilepsy brain image
Trayt's mobile app aims to help track and treat autism, ADHD other neurodevelopmental brain disorders. (CC0 Creative Commons)

Trayt, a Redwood City, California-based data analytics company, has released a mobile application designed to help diagnose, track and treat patients with autism, ADHD and other neurodevelopmental brain disorders.

The app allows patients and caretakers to monitor behavioral and nonbehavioral symptoms by using a comorbid rating scale and can accurately measure the effectiveness of treatments. The collected data is analyzed and viewed on a dashboard that gives progress reports and personalized, actionable insights, the company said.

Because patients with brain-based disorders tend to be diagnosed and treated by different care teams that often don’t communicate, overlapping conditions can be overlooked and care may not be optimized. 

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

“As a parent of a child with a multisystem neurological disorder, I’ve experienced firsthand the defeated feeling of walking out of a doctor’s appointment after being redirected time and time again to see a new physician to treat a new symptom,” Malekeh Amini, founder and CEO of Trayt, said in a statement. “Instead of considering whether these conditions were related or causal, they were treated individually and the coordination and care in between was completely left up to me.”

Trayt is designed to standardize measurement with an overall view of the patient that takes into account all factors that may contribute to more successful outcomes.

Read more on

Suggested Articles

Janssen is planning its first completely virtual clinical trial, using personal smartphones and wearable devices with no in-person site visits.

Sensyne Health aims to bring its AI tools to America, and it’s enlisting IT giant Cognizant and data infrastructure specialist Agorai to help.

Daré Bioscience added a microchip-based implant to its pipeline and reported data from a pre-pivotal study of a hormone-free contraceptive ring.